Patricia Braly, MD
Gynecologic Oncology · Covington, LANPI 1457316283
Payments from drug & device makers
Across 806 payments — averaging $7431.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$2.1M
- Merck$2.1M
- Tesaro, Inc.$1.3M
- AbbVie$108K
- AstraZeneca$94K
- Astrazeneca UK Limited$85K
- plus $157K from 32 others
Across 5 payments — averaging $2496.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Clovis Oncology, Inc.$12K
- Tesaro, Inc.$150
What the payments were for
- Consulting fees$17,44113%
- Speaking & faculty fees$91,40070%
- Travel & lodging$14,05611%
- Food & beverage$7,3006%
- Education$2850%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 166 | $2,149,360 |
| Merck | 133 | $2,126,760 |
| Tesaro, Inc. | 80 | $1,269,915 |
| AbbVie | 25 | $108,074 |
| AstraZeneca | 80 | $93,978 |
| Astrazeneca UK Limited | 8 | $84,881 |
| Immunogen, Inc. | 38 | $71,729 |
| Organon | 2 | $19,400 |
| F. Hoffmann-la Roche AG | 2 | $15,275 |
| Astrazeneca AB | 1 | $12,600 |
| Springworks Therapeutics, Inc. | 155 | $11,754 |
| Clovis Oncology, Inc. | 26 | $10,395 |
| Eisai Inc. | 20 | $5,911 |
| Seagen Inc. | 8 | $5,377 |
| Boehringer Ingelheim International GmbH | 2 | $1,942 |
| Intuitive Surgical | 9 | $958 |
| Genmab U.S., Inc. | 15 | $477 |
| Aspira Women's Health Inc | 2 | $200 |
| Amgen | 1 | $125 |
| Myriad Genetic Laboratories, Inc. | 6 | $108 |
| Bayer | 1 | $107 |
| Otsuka America Pharmaceutical, Inc. | 1 | $100 |
| Therapeuticsmd, Inc. | 5 | $84 |
| Astellas Pharma US Inc | 3 | $80 |
| Applied Medical Resources Corporation | 1 | $50 |
| Biom'up France SAS | 1 | $48 |
| Pacira Pharmaceuticals Incorporated | 2 | $43 |
| Caris MPI, Inc. | 2 | $42 |
| Pfizer | 2 | $38 |
| Foundation Medicine, Inc. | 1 | $36 |
| BD | 1 | $31 |
| Davol Inc. | 1 | $25 |
| Duchesnay USA Incorporated | 1 | $25 |
| Kyowa Kirin, Inc. | 1 | $19 |
| Cumberland Pharmaceuticals, Inc. | 1 | $17 |
| Baxter Healthcare | 1 | $17 |
| Meditrina | 1 | $17 |
| Hologic Sales And Service, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few gynecologic oncology providers in Louisianato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Estradiol | 60 | $5,838 |
| ImvexxyEstradiol | 11 | $3,062 |
| Clobetasol Propionate | 44 | $1,842 |
| Mupirocin | 58 | $439 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 64 | $393 |
| Ondansetron OdtOndansetron | 18 | $385 |
| Chlorhexidine Gluconate | 59 | $234 |
| Gabapentin | 11 | $59 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Therapeuticsmd, Inc.Imvexxy | $84 | $3,06211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few gynecologic oncology providers in Louisianaon file to place this against a meaningful peer group, so we don't.
Other gynecologic oncology in Covington
- Destin BlackShreveport$4.7M
- Katrina WadeNew Orleans$1.1M
- Andrew GreenShreveport$818K
- Amma AgyemangMetairie$23K
- Jacob EstesNew Orleans$16K
- Milton FortBaton Rouge$9K
- Jessica ShankNew Orleans$4K
- David BarringtonNew Orleans$2K
- Diogo TorresNew Orleans$2K
- Pui ChengNew Orleans$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.